Loading stock data…
$2.43-0.13 (-5.08%)
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Altimmune, Inc. in the Healthcare sector is trading at $2.43 with a market capitalization of $532M. Wall Street consensus targets $17.11 (9 analysts), implying a +604.2% move over the next 12 months. The stock is currently near its 52-week low of $2.43, remaining 28.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: RSI 5 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $26,000↑ | $5,000 | $5,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.23M↓ | -$24.24M↑ | -$28.89M↓ | -$20.86M↑ | -$22.92M |
| Net Income | -$22.82M↓ | -$22.56M↑ | -$27.36M↓ | -$19.01M↑ | -$22.15M |
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial ...